Coherus Biosciences | CHRS - Interest Expense On Debt


Coherus Biosciences reported $2.25M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 688M 58M Sep/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 342.13M 7.53M Sep/2026
ALKERMES USD 27.55M 1.63M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 653M 94.99B Sep/2026
Baxter International USD 64M 14M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 316M 201.3M Sep/2026
Fujifilm JPY 2.46B 1.6B Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Merck USD 525M 46M Jun/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Pacira USD 112.4M 108.78M Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026
Xencor USD 4.11M 3.24M Sep/2026
Zoetis USD 62M 1000K Sep/2026